Inhibition of growth factor mitogenicity and growth of tumor cell xenografts by a sulfonated distamycin a derivative

Pharmacology

Volumn 55, Issue 6, 1997, Pages 269-278

  Finch, Paul W ^a   Yee, Lorrin K ^a   Chu, Ming Y W ^a   Chen, Tian M ^a   Lipsky, Milton H ^a   Maciag, Thomas ^a   Friedman, Stanley ^c   Epstein, Mel H ^b   Calabresi, Paul ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c HOLLAND LABORATORY   (United States)

Author keywords

Autocrine growth promoting pathways; Growth factors, paracrine actions; Growth inhibition; Suramin Xenograft

Indexed keywords

DISTAMYCIN A DERIVATIVE; FIBROBLAST GROWTH FACTOR 1; GROWTH FACTOR; SIGNAL PEPTIDE; SURAMIN;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FIBROBLAST; GENE FUSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MITOGENICITY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0030727495     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139538     Document Type: Article

References (36)

1. Aaronson SA: Growths factors and cancer. Science 1991:254:1146-1153.
2. Folkman J. Klagsbrun M: Angiogenic factors. Science 1987:235:442-447.
3. Folkman J. Watson K. Ingbcr D. Nanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989: 339:58-61.
4. La Rocca RV. Stein CA, Danesi R. Jamis-Dow C. Weiss GH. Myers C: Suramin in adrenal cancer: Modulation of steroid hormone production, cytotoxicity in vitro, and clinical antitumor effect. J Clin Endocrinol Metab 1990:71:497-504.
5. Myers CM. Cooper M. Stein C. La Rocca RV. Wailher MM. Weiss G. Choyke P. Dawson N, Steinberg S. Uhrich MM. Cassidy J. Kohler DR. Trepel J. Linehan DR: Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992;10:881-889.
6. Reed E, Cooper MR. La Rocca RV, Bostick-Bruton F. Myers CE: Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer 1992:28a:864-866.
7. La Rocca RV. Stein CA. Danesi R. Cooper MR. Uhrich M, Myers CE: A pilot study of suramin in the treatment of renal metastatic carcinoma. Cancer 1991:67:1509-1513.
8. Motzer RJ. Nanus DM. O'Moore P. Seller HL Bajorin DF. Reuter V. Tong WP. Ivcrscn J. Louison C. Albino AP. Bosl GJ: Phase II trial of suramin in patients with advanced renal cell carcinoma: Treatment results. pharmacokinetics, and tumor growth factor expression. Cancer Res 1992;52:5775-5779.
9. Stein CA: Suramin: A novel antineo-plastic agent with multiple potential mechanisms of action. Cancer Res 1993:53:2239-2248.
10. Coffey RJ. Leof EB. Shipley GD. Moses III.: Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-28 cells. J Cell Physiol 1987:132:143-148.
11. Vaisman N. Gospodarowicz D. Ncufcld G: Characterization of the receptors for vascular endothelial cell growth factor. J Biol Chcm 1990:256:19461-19466.
12. Minniti CP. Maggi M. Helman LJ: Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 1992:52:1830-1835.
13. Pcscnti F. Sola F. Mongel IN, Gran-di M. Spreattio F: Suramin prevents neovascularization and:umor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992:66:367-372.
14. Danesi R. Del-Bianchi S. Soldani P. Campagni A. La Rocca RV. Myers CE. Paparclli A. Del-Tacca M: Suramin inhibits bFGF-induccd endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane. Br J Cancer 1993:68: 932-938.
15. Takano S. Gatelv S. Neville ME. Herblin WF. Gross JL. Engelhard H. Pcrricone M. Eidsvoog K. Brem S: Suramin, an anticancer ar.d an-giosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation. and induction of urokinase-type plasminogenc activator. Cancer Res 1994:54:2654-2660.
16. Stein CA, La Rocca R, Myers C: Suramin: An old compound with new biology. PPO Updates. May 1990. vols 4-5.
17. Coimci M. Pastori W. Mariani M, Sola F, Mongelli N: New sulfonated distamycin A dérivâtes with bFGF complexing activity. Biochcm Pharmacol 1994:47:295-302.
18. Jainchill JL, Aaronson SA. Todaro GJ: Murine sarcoma and leukemia viruses: Assay using cloned lines of contact-inhibited mouse cells. J Virol 1969:4:549-553.
19. Forough R. Zhan X. MacPhec M. Friedman S. Engleka KA. Sayers T, Wiltrout RH, MaciagT: Differential transforming activities of non-se-crctcd and secreted forms of human fibroblast growth factor-1. J Biol Chem 1993:268:2960-2968.
20. Chu E. Chu MYW. Darnowski JW. Chen ZH. Pan BC. Chu SH: Enhancement of 5-fluoro-2'-deoxyu-ridine antineoplastic activity by 5'-benzyloxybcnzylacvclouridine in a human colon carcinoma cell line. Cancer Res 1992:52:1729-1736.
21. Chu MYW. Chu E. Naguib FNM, el Kouni MH. Chu SH. Cha S, Cala-bresi P: Potentiation of FdUrd antineoplastic activity by the uridine phosphorvlase inhibitors benzylacy-clouridine (BAU) and bcnzyloxy-benzylacvclouridine (BBAU). Cancer Res 1984:26:1852-1856.
22. Fleming TP. Matsui T. Molloy CJ. Robbins KC. Aaronson SA: Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors. Proc Natl Acad Sci USA 1989:86:8063-8067.
23. Bctsholtz C. Johnsson A, Heldin C-H. Wcstcrmark B: Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc Natl Acad Sci USA 1986;83:6640-6444.
24. Fanttini J. Rogoni JB, Roccabianca M. Pommier G. Marvaldi J: Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colonic adenocarcinoma cell clone HT29-D4. J Biol Chcm 1989;264:10282-10286.
25. Vignion F, Prebois C. Rochefort FI: Inhibition of breast cancer growth by suramin. J Natl Cancer Inst 1992:84:38-42.
26. Fockcns JA. Sieuwerts AM. Stuur-man-Smccts EM. Dorssers LC. Berns EM. Klijn JG: Pleiotropic actions of suramin on the proliferation of human breast-cancer cells in vitro. Int J Cancer 1992:51:439-444.
27. Putnam EA. Yen N, Gallick GE. Steck PA. Fang K. Akpakip B. Gazdar AF. Roth JA: Autocrine growth stimulation by transforming growth factor alpha in human non-small lung cancer. Surg Oncol 1992:1:49-60.
28. Favoni RE. Ravera F. Pirani P. Ar-dizzoni A. Noonan D. de Cupis A: Suramin interferes with auto/para-crine insulin-like growth factor I controlled proliferative loop on human lung cancer cell lines. Eur J Pharmacol 1994,264:199-206.
29. Kim J. Sherwood E, Sutkowski D, Lee C, Kozlowski J: Inhibition of prostatic tumor proliferation by suramin: Alterations in TGF-a mediated autocrine growth regulation and cell cycle distribution. J Urol 1991:146:171-176.
30. Knabbe C. Kellner U, Schmahl M. Voigt K: Growth factors in human prostate cancer cells: Implications for improved treatment of prostate cancer. J Steroid Biochem Mol Biol 1991:40:185-192.
31. La Rocca RV. Dancsi R. Cooper MR. Jamis-Dow C. Ewing W, Lutetian M. Myers CE: Effect of suramin on human prostate cancer cells in vitro. J Urol 1991:145:393-398.
32. Jindal H. Anderson CW, Davies RG. Vishwanatha JK: Suramin affects DNA synthesis in Hcla cells by inhibition of DNA polymerases. Cancer Res 1990:50:7754-7757.
33. Bojanski K. Lelicvre S, Markovits J. Coupric J. Jacquemin-Sabon A. Larsen SK: Suramin is an inhibitor of DNA topoisonterase 11 in vitro and in Chinese hamster fibrosarcoma cells. Proc Natl Acad Sci USA 1992:89:3025-3029.
34. Sola F. Farao M. Pescnti E. Marsiglio A. Mongelli N. Grandi M: Antitumor activity of FCE 26644. a new growth factor complexing molecule. Cancer Chcmothcr Pharmacol 1995:36:217-222.
35. Kikuchi Y. Hirata J. Hisano A, Tode T, Kita T. Nagata I: Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplalinum (II). Gynecol Oncol 1995:58:11-15.
36. Vincent TS. Hazen-Martin DJ. Garvin AJ: Inhibition of insulin-like growth factor II autocrine growth of Wilm’s tumor by suramin in vitro and in vivo. Cancer Lett 1996:103: 49-56